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How to cite this article: Nagar VS, Chaterjee R, Sood A, Sajjan B, Kaushik A, Vyahalkar SV. functions normalized by the 12 th cycle. Anti-CFH antibodies were repeated and found to have decreased to 191.07 AU/ml. Peripheral smear showed a complete absence of schistocytes with urine negative for hemosiderin. He later developed sudden onset severe headache followed by loss of vision progressing to generalized tonic-clonic seizures and status epilepticus. Blood pressure was increased at 200/140 mmHg. He was intubated and later successfully weaned off mechanical ventilation. A magnetic resonance imaging (MRI) brain revealed posterior reversible encephalopathy with altered signal intensity in a subcortical white matter of the bilateral parietal, occipital, posterior temporal lobes and cerebellar hemispheres [ Figure  1 ]. He subsequently developed three more episodes of status epilepticus with posterior reversible encephalopathy. Blood pressure control was achieved using nifedipine, labetalol, and telmisartan. Seizures were controlled on phenytoin, levetiracetam, and clobazam. Severe skin rashes developed almost 2 months into admission: Centripetal in development with mucosal involvement and was diagnosed as StevenJohnson syndrome [ Figure 2 ]. Phenytoin was withheld and the lesions resolved. He was started on further immunosuppression with steroids and azathioprine and discharged on day 91 of admission in complete clinical and hematological remission. dIscussIon aHUS is a thrombotic microangiopathy resulting from mutations in CFH, complement factor I, membrane cofactor protein (CD46), C3, thrombomodulin, CFH-receptor 5, or from autoantibodies to CFH. CFH mutations are the most common affecting 25% cases of aHUS. [3] Autoantibodies to CFH reported in 4%-14% of all cases, however, are much more common in cases with early onset of disease and are present in up to 25% of such cases. [4] Our patient had an early onset of disease with strongly positive autoantibodies to CFH. Autoantibodies to CFH prevent cell surface protection by CFH, chiefly by inhibiting binding to C3b. Low C3 levels are hence often demonstrated in this autoimmune variant of the disease. aHUS may be suspected in patients with typical history along with proven negative stool cultures for Shiga-like toxin and normal ADAMTS13 activity and can be confirmed by genetic assays, though empiric treatment is often initiated. The autoimmune variant, however, as in our case may not have a genetic focus and can be diagnosed by high levels of antibodies to CFH (2043 AU/ml in our case). The overall aHUS has incomplete penetrance, and an infectious trigger is often associated with the disease precipitating. [5] Our case presented with a high-grade fever of undocumented etiology which was probably the trigger for complement activation.
Globally, eculizumab, the monoclonal antibody to C5b, has found acceptance in the treatment of aHUS. [6] The limiting factor is the cost of eculizumab therapy, especially in developing countries. Plasma exchange had been the gold standard in the treatment of aHUS before eculizumab. Guidelines issued in 2009 recommended initial daily plasma exchange (50-70 ml/kg) with further titration of frequency according to clinical response. [7] Our patient received an initial seven cycles of daily plasma exchange followed by gradual tapering with monitoring of hematological and renal parameters which showed complete normalization by the 12 th cycle. Further, four cycles were continued till antibodies to CFH were almost undetectable. CFH-related aHUS, similar to Page no. 43 our patient, has been documented to respond better to plasma exchange. [8] Our patient did not develop any requirement for renal replacement therapy with hemodialysis as is the norm in a majority of cases of aHUS. This can be attributed to rapid initiation of plasma exchange.
Hypertension is a common complication of aHUS but developed late in the course of treatment in our patient. Seizures are the most common neurological involvement in aHUS. Posterior reversible encephalopathy with associated loss of vision may have an identical presentation as cerebral thrombotic microangiopathy. The latter can be differentiated on the basis of asymmetry of the lesions on MRI. [9] Although neurological sequelae respond best to eculizumab, our patient was already in remission at the time of onset. His symptoms resolved with control of blood pressure. StevenJohnson syndrome was probably a coincidental reaction to phenytoin and does not relate to aHUS in the available literature.
Cyclophosphamide, mycophenolate mofetil, azathioprine and steroids, all have supporting literature for maintenance therapy. [10] We chose azathioprine in view of relative ease of dosing.
The prognosis of aHUS remains guarded. In patients with CFH autoantibodies 36.5%-63% progress to mortality or end-stage renal disease in the long-term. [2, 5] Our patient remains in clinical remission at 6 months on follow-up.
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